Status:
RECRUITING
A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-80 years
Brief Summary
This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hema...
Eligibility Criteria
Inclusion
- Patient
- Diagnosis of Multiple Myeloma after January 1, 2017.
- Karnofsky Performance Status \> 70%
- ≥ 2 lines of prior therapy
- Anticipated to start new a line of therapy for RRMM within the next 12 months
- Age 18-80 years of age.
- English or Spanish speaking.
- Willing to provide informed consent
- Willing to perform study procedures.
- Physician Investigator
- Be a Co-Investigator
- Agree to comply with study procedures
Exclusion
- Patient
- Active CNS disease
- Patients who already have a definitive plan are to be excluded
Key Trial Info
Start Date :
November 3 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 3 2029
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06126341
Start Date
November 3 2023
End Date
May 3 2029
Last Update
October 23 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Hartford Healthcare Alliance
Hartford, Connecticut, United States, 06102
2
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States, 07920
3
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States, 07748
4
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States, 07645